You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

14 search results for: disease progression

Impact of Delayed EoE Diagnosis on <b>Disease</b> <b>Progression</b> and QoL

expert video

Impact of Delayed EoE Diagnosis on Disease Progression and QoL

2 min

Gastroenterology

Join Prof. Arjan Bredenoord as he discusses the importance of early diagnosis of EoE.

Gap in Care Leads to <b>Progression</b> of Fibrosis in EoE

expert video

Gap in Care Leads to Progression of Fibrosis in EoE

1 min

Gastroenterology

Dr. Evan Dellon discusses the clinical implications of gaps in medical care on the risk of fibrotic progression in EoE.

interactivity

GINA Guidelines For Improved Outcomes With Effective Management of Pediatric Asthma

5 min

Pulmonology

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.

expert video

Managing the Risk of Fibrostenosis in EoE

2 min

Gastroenterology

Hear from Drs. Jason Lee, Kathryn Peterson, Seema Aceves, and Ikuo Hirano on disease progression and the importance of managing fibrostenotic risk in EoE.

Worsening <b>Disease</b> Results in a Vicious Cycle of COPD

interactivity

Worsening Disease Results in a Vicious Cycle of COPD

5 min

Pulmonology

Learn about the disease burden and heterogeneity of COPD

Importance of Assessing Multiple <b>Disease</b> Domains in EoE

expert video

Importance of Assessing Multiple Disease Domains in EoE

2 min

Gastroenterology

Prof. Arjan Bredenoord and Dr. Evan Dellon emphasize the need to assess multiple disease domains to get the complete picture of patients’ EoE.

EoE: A Chronic, Progressive, Type 2 Inflammatory <b>Disease</b>

Infographic

EoE: A Chronic, Progressive, Type 2 Inflammatory Disease

5 min

Gastroenterology

Learn about key drivers of type 2 inflammation in EoE and how they mediate progressive esophageal remodeling and impact patient burden.

videoanimation

EoE Burden and Pathophysiology of Type 2 Inflammation

3 min

Gastroenterology

Learn about the significant burden that patients with EoE experience and the role of type 2 inflammation in this chronic, progressive disease.

expert video

More Than Eosinophils: A Closer Look at the Pathophysiology of EoE

20 min

Gastroenterology

Join Prof. Kathryn Peterson for an expert review on how different immune cells and inflammatory mediators contribute to the pathogenesis of EoE.

expert video

Complex EoE Pathophysiology Beyond Esophageal Eosinophilia

2 min

Gastroenterology

Dr. Jonathan Spergel and Prof. Arjan Bredenoord highlight the importance of different immune cells in type 2 inflammation in EoE.

expert video

Interplay of Barrier Dysfunction and Type 2 Inflammation in EoE

2 min

Gastroenterology

Learn from Prof. Seema Aceves about the interconnectivity of type 2 inflammation and barrier dysfunction in mediating EoE pathophysiology.

expert video

Patient Burden in Eosinophilic Esophagitis

3 min

Gastroenterology

Drs. Kathryn Peterson and Ikuo Hirano and Profs. Ingrid Terreehorst and Arjan Bredenoord highlight the impact and burden of EoE on the quality of life of patients.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region